[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657007":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":11,"studyPopulation":11,"armGroups":32,"interventions":47,"overallOfficials":11,"centralContacts":62,"locations":68,"responsibleParty":87,"collaborators":11,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":11,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":11,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":11,"overallStatus":108,"whyStopped":11,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Overall survival (OS)",null,"Up to 48 months",[14,16,18,20],{"measure":15,"description":11,"timeFrame":12},"Progression-free survival (PFS)",{"measure":17,"description":11,"timeFrame":12},"Objective Response Rate (ORR)",{"measure":19,"description":11,"timeFrame":12},"Duration of response (DoR)",{"measure":21,"description":11,"timeFrame":12},"Occurrence of adverse event (AE) and serious adverse event (SAE)",{"allocation":23,"interventionModel":24,"interventionModelDescription":11,"primaryPurpose":25,"observationalModel":11,"timePerspective":11,"maskingInfo":26},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":27,"maskingDescription":11,"whoMasked":28},"TRIPLE",[29,30,31],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR",[33,41],{"label":34,"type":35,"description":36,"interventionNames":37},"ZG005 + Etoposide + Cisplatin","EXPERIMENTAL","Treatment arm",[38,39,40],"Drug: ZG005 for Injection","Drug: Etoposide Injection","Drug: Cisplatin Injection",{"label":42,"type":43,"description":44,"interventionNames":45},"ZG005 Placebo + Etoposide + Cisplatin","ACTIVE_COMPARATOR","Control arm",[39,40,46],"Drug: ZG005 placebo for injection",[48,53,56,59],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":11},"DRUG","ZG005 for Injection","Intravenous infusion",[34],{"type":49,"name":54,"description":51,"armGroupLabels":55,"otherNames":11},"Etoposide Injection",[34,42],{"type":49,"name":57,"description":51,"armGroupLabels":58,"otherNames":11},"Cisplatin Injection",[34,42],{"type":49,"name":60,"description":51,"armGroupLabels":61,"otherNames":11},"ZG005 placebo for injection",[42],[63],{"name":64,"role":65,"phone":66,"phoneExt":11,"email":67},"Shangdi Ning","CONTACT","+86-0512-57309965","ningsd@zelgen.com",[69],{"facility":70,"status":11,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450052","China","CN",{"type":77,"coordinates":78},"Point",[79,80],113.64861,34.75778,{"lat":80,"lon":79},[83],{"name":84,"role":65,"phone":85,"phoneExt":11,"email":86},"Lijie Song","13939020459","lijiesongcn@hotmail.com",{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100657007","phase-3-zg005-plus-etoposide-and-cisplatin-vs-etoposide-and-cisplatin-as-first-line-treatment-for-advanced-neuroendocrine-carcinoma-100657007",false,"NCT07833839","ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma","A Randomized, Double-Blind, Controlled, Multicenter Phase III Clinical Trial of ZG005 in Combination With Etoposide and Cisplatin Versus Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma","Inclusion Criteria:\n\n* Participant has fully understood the trial, agrees to comply with the study treatment regimen and visit schedule, and voluntarily signs the informed consent form (ICF).\n* Male or female participants aged 18 to 75 years (inclusive) at the time of signing the informed consent form (ICF).\n* Life expectancy of more than 3 months.\n* Histologically confirmed recurrent or metastatic neuroendocrine carcinoma (NEC).\n* The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\\~1.\n\nExclusion Criteria:\n\n* History, computed tomography (CT), or magnetic resonance imaging (MRI) findings suggestive of central nervous system (CNS) metastases or leptomeningeal metastases.","ALL","18 Years","75 Years",{"count":100,"type":101},440,"ESTIMATED","INTERVENTIONAL",[104],"PHASE3","This is a randomized, double-blind, controlled, multicenter Phase III study evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of ZG005 combined with the EP regimen (etoposide plus cisplatin) in participants with advanced NEC who are naive to systemic therapy.",[107],"Neuroendocrine Carcinomas (NEC)","NOT_YET_RECRUITING","2026-09-16",{"date":111,"type":112},"2026-09-22","ACTUAL",{"date":114,"type":101},"2026-10",{"date":116,"type":101},"2031-12",{"name":5,"class":6},1]